Profound Medical CEO and leadership

Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc. (NASDAQ:PROF, TSX:PRN), a commercial stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.Prior to joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a start-up to one of the fastest-growing, NASDAQ listed medical technology companies in North America, with a market cap of over $ 1 Billion USD. During his tenure, Novadaq pioneered the field of fluorescence imaging and built a powerful new ecosystem that provides clinically relevant imaging solutions to improve outcomes at multiple points throughout the patient care continuum.Arun previously served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Under his leadership, Cedara achieved profitability and was ultimately acquired. Today, the company’s imaging platform and its big data collection are part of IBM’s Watson program.Arun also serves as a member of the board of directors or advisor to growth oriented life science companies. Earlier in his career, Arun held executive positions at Tenneco Inc. and Hercules Inc. in the areas of business development, technology development and mergers/acquisitions. He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., Cardeas Pharma, HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and Novadaq Technologies. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing. Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.